08:00 , Dec 5, 2011 |  BC Week In Review  |  Company News

MabCure, Biotech Investment deal

MabCure granted Biotech Investment an exclusive, worldwide license to undisclosed MabCure hybridoma clones producing antibodies against prostate cancer. MabCure received $500,000 up front and is eligible for a 12.5% royalty. Biotech will also issue MabCure...